Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2seventy bio, Inc. - Common Stock (NQ: TSVT ) 4.400 +0.060 (+1.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about 2seventy bio, Inc. - Common Stock < Previous 1 2 3 Next > TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm October 08, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm September 30, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire 2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance September 25, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference August 29, 2024 From 2seventy bio Via Business Wire 2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress August 07, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 August 05, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million June 26, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Participate in Upcoming Investor Conferences May 23, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress May 08, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 May 03, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron April 01, 2024 From 2seventy bio, Inc. Via Business Wire U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy April 05, 2024 From Bristol Myers Squibb Via Business Wire 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors March 20, 2024 From 2seventy bio, Inc. Via Business Wire FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 15, 2024 From Bristol Myers Squibb Via Business Wire 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress March 05, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences March 01, 2024 From 2seventy bio, Inc. Via Business Wire Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise February 27, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... Via Newsfile 2seventy bio to Participate in Upcoming Investor Conferences February 05, 2024 From 2seventy bio, Inc. Via Business Wire Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study February 05, 2024 From Bristol Myers Squibb Via Business Wire 2seventy bio Announces New Strategic Path Forward January 30, 2024 From 2seventy bio, Inc. Via Business Wire Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 December 11, 2023 From Bristol Myers Squibb Via Business Wire 2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel) December 11, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Reiterates Commitment to Maximizing Shareholder Value December 06, 2023 From 2seventy bio, Inc. Via Business Wire Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma November 20, 2023 From Bristol Myers Squibb Via Business Wire 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress November 14, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023 November 10, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway September 12, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies September 12, 2023 From 2seventy bio Via Business Wire 2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference September 06, 2023 From 2seventy bio, Inc. Via Business Wire 2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress August 14, 2023 From 2seventy bio, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
